Tgfbeta-rII promoter polymorphisms
First Claim
Patent Images
5-1. The method of claim 1, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fragment analysis, oligonucleotide ligation assay or allele specific PCR.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are single nucleotide polymorphisms (SNPs) associated with end stage renal disease, breast cancer, lung cancer, and prostate cancer. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.
-
Citations
25 Claims
-
5-1. The method of claim 1, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fragment analysis, oligonucleotide ligation assay or allele specific PCR.
-
6. An isolated polynucleotide comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 1, or the complement thereof, and containing at least one single nucleotide polymorphism at position 945, 983, or 1009 of SEQ ID NO;
1 wherein said at least one single nucleotide polymorphism is associated with a 5 disease, condition or disorder selected from the group consisting of end stage renal disease, lung cancer, breast cancer, and prostate cancer.
- 1, or the complement thereof, and containing at least one single nucleotide polymorphism at position 945, 983, or 1009 of SEQ ID NO;
-
7. The isolated polynucleotide of claim 7, wherein at least one single nucleotide polymorphism is selected from the group consisting of G945→
- T, G983→
M, and G1 009→
W and the complements thereof namely C945→
A, C983→
K, and C1009→
W. - View Dependent Claims (8, 9)
- T, G983→
-
10. The isolated nucleic acid sequence of claim 10, wherein said detectable label is selected from the group consisting of radionuclides, fluorophores or fluorochromes, peptides, enzymes, antigens, antibodies, vitamins or steroids.
-
11. A kit comprising at least one isolated polynucleotide of at least 10 contiguous nucleotides of SEQ ID NO:
- 1 or the complement thereof, and containing at least one single nucleotide polymorphism associated with a disease, condition, or disorder selected from the group consisting of end stage renal disease, lung cancer, breast cancer, and prostate cancer; and
instructions for using said polynucleotide for detecting the presence or absence of said at least one single nucleotide polymorphism in said nucleic acid.
- 1 or the complement thereof, and containing at least one single nucleotide polymorphism associated with a disease, condition, or disorder selected from the group consisting of end stage renal disease, lung cancer, breast cancer, and prostate cancer; and
- 12. The kit of claim 12 wherein said at least one single nucleotide polymorphism is located at position 945, 983, or 1009 of SEQ ID NO:
-
13. The kit of claim 13 wherein said at least one single nucleotide polymorphism is selected from the group consisting of G945→
- T, G983→
M, and G1009→
W and the complements thereof namely C945→
A, C983→
K, and C1009→
W.
- T, G983→
-
16. The kit of claim 16, wherein said label is chosen from the group consisting of radionuclides, fluorophores or fluorochromes, peptides enzymes, antigens, antibodies, vitamins or steroids.
-
17. A kit comprising at least one polynucleotide of at least 10 contiguous nucleotides of SEQ ID NO:
- 1 or the complement thereof, wherein the 3′
end of said polynucleotide is immediately 5′
to a single nucleotide polymorphism site associated with a genetic predisposition to disease, condition, or disorder selected from the group consisting of end stage renal disease, lung cancer, breast cancer, and prostate cancer; and
instructions for using said polynucleotide for detecting the presence or absence of said single nucleotide polymorphism in a biological sample containing nucleic acid.
- 1 or the complement thereof, wherein the 3′
-
18. The kit of claim 18, wherein said single nucleotide polymorphism site is located at position 945, 983 or 1009 of SEQ ID NO:
- 1.
-
19. The kit of claim 19, wherein said at least one polynucleotide further comprises a detectable label.
-
20. The kit of claim 20, wherein said detectable label is chosen from the group consisting of radionuclides, fluorophores or fluorochromes, peptides, enzymes, antigens, antibodies, vitamins or steroids.
-
21. A method for treatment or prophylaxis in a subject comprising:
-
obtaining a sample of biological material containing nucleic acid from a subject;
analyzing said nucleic acid to detect the presence or absence of at least one single nucleotide polymorphism in SEQ ID NO;
1 or the complement thereof associated with a disease, condition, or disorder selected from the group consisting of end stage renal disease, lung cancer, breast cancer, and prostate cancer; and
treating said subject for said disease, condition or disorder.
-
- 22. The method of claim 22 wherein said nucleic acid is selected from the group consisting of DNA, cDNA, RNA and mRNA.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeViral Therapeutics, Inc. (Vybion, Inc.)
-
Original AssigneeViral Therapeutics, Inc. (Vybion, Inc.)
-
InventorsMoskowitz, David W., Henderson, Lee A.
-
Application NumberUS10/275,098Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current435/6CPC Class CodesC12Q 1/6886 for cancer immunoassay for ...C12Q 2600/106 Pharmacogenomics, i.e. gene...C12Q 2600/156 Polymorphic or mutational m...
